• Product name
    Anti-VLDL Receptor / VLDL-R antibody
    See all VLDL Receptor / VLDL-R primary antibodies
  • Description
    Rabbit polyclonal to VLDL Receptor / VLDL-R
  • Host species
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rat, Rabbit, Cow
  • Immunogen

    Synthetic peptide corresponding to Human VLDL Receptor/ VLDL-R aa 500-600 conjugated to keyhole limpet haemocyanin.
    (Peptide available as ab102057)

  • Positive control
    • This antibody gave a positive signal in Human ovary tissue lysate.
  • General notes

    Previously labelled as VLDL Receptor. 


Our Abpromise guarantee covers the use of ab92943 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 130 kDa (predicted molecular weight: 96 kDa).


  • Function
    Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
  • Tissue specificity
    Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
  • Involvement in disease
    Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
  • Sequence similarities
    Contains 3 EGF-like domains.
    Contains 8 LDL-receptor class A domains.
    Contains 6 LDL-receptor class B repeats.
  • Post-translational
    Ubiquitinated at Lys-839 by MYLIP leading to degradation.
  • Cellular localization
    Membrane. Membrane > clathrin-coated pit.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ35024 antibody
    • Very low density lipoprotein receptor antibody
    • Very low-density lipoprotein receptor antibody
    • VLDL R antibody
    • VLDL receptor antibody
    • VLDL-R antibody
    • VLDLR antibody
    • VLDLR_HUMAN antibody
    • VLDLRCH antibody
    see all


  • Anti-VLDL Receptor / VLDL-R antibody (ab92943) at 1 µg/ml + Human ovary tissue lysate - total protein (ab30222) at 10 µg

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 96 kDa
    Observed band size: 130 kDa
    why is the actual band size different from the predicted?
    Additional bands at: 24 kDa, 63 kDa. We are unsure as to the identity of these extra bands.

    Exposure time: 16 minutes

    The predicted molecular weight of VLDL Receptor / VLDL-R is 96 kDa (SwissProt), however we expect to observe a banding pattern at 130 kDa. VLDL Receptor / VLDL-R contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.


This product has been referenced in:
  • Shin KC  et al. Macrophage VLDLR mediates obesity-induced insulin resistance with adipose tissue inflammation. Nat Commun 8:1087 (2017). Read more (PubMed: 29057873) »
  • Okoro EU  et al. A Subregion of Reelin Suppresses Lipoprotein-Induced Cholesterol Accumulation in Macrophages. PLoS One 10:e0136895 (2015). Read more (PubMed: 26317415) »
See all 4 Publications for this product

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

Western blot
Mouse Tissue lysate - whole (Kidney, Testes, Cerebellum and spleen (see figure))
Gel Running Conditions
Reduced Denaturing (4-12% Bis-Tris gel (Novex))
Loading amount
15 µg
Kidney, Testes, Cerebellum and spleen (see figure)
Blocking step
Milk, serum (see figure) and BSA tested as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Oct 30 2012


Sign up